Pfizer's CEO Goes All In Albert Bourla clearly has no plans to retire. Rather, the 64-year-old Pfizer CEO is in the thick of it — diving into the stock market, putting his own money where his mouth is.

On August 12, Pfizer's stock was hovering around $26 per share. A less-than-dignified position for a company with over $60 billion in annual revenue — compared to Merck at over $130 and Johnson & Johnson breaking past $250. On the same day, Bourla spent approximately $1 million to buy more shares.

One million dollars is negligible for a company with a market cap exceeding $150 billion. But what makes this notable is that it marks the first time since Bourla took the helm in 2019 that he has used his own money to buy company stock on the open market.

Previously, Bourla's Pfizer shares all came from equity incentives in his compensation package. His total 2025 compensation reached $27.6 million, including $9.4 million in stock awards and $9 million in options.

Even more telling is the timing. Just one week earlier, on August 4, Pfizer released its Q2 2026 earnings.

During the reporting period, Pfizer posted revenue of $15.03 billion, up 3% year-over-year, beating market expectations of $14.41 billion. Non-COVID products grew 5% operationally, while launched and acquired products grew 18%. The company also raised the midpoint of its full-year revenue guidance by $500 million.

The market's reaction, however, was muted. After the earnings release, Pfizer shares rose but lacked follow-through momentum. The average target price among 28 Wall Street analysts is $28.64 — implying less than 10% upside.

Investor patience appears to be wearing thin.

To send a signal of confidence, in addition to Bourla, Pfizer directors Ronald Blaylock and Mortimer Buckley collectively purchased $2 million worth of company stock on August 5. A wave of insider buying quietly unfolded amid the earnings season noise.

Chapter 1: Collective Action

On August 5, the day after the earnings release, two directors made the first move.

Blaylock bought 39,000 shares at $25.46 each, and Buckley bought 37,600 shares at $25.52 each — together investing about $2 million.

On the same day, Pfizer Senior Vice President and Finance Director Jennifer Damico went the opposite direction, selling 3,278 shares at $25.40, cashing out about $83,000. It was her second sale in a few weeks; the previous one was in early June.

Sales alongside purchases are not unusual in insider transactions. But what truly caught the market's attention was Bourla's move.

On August 12, Bourla bought 38,000 shares at $26.34 each. After the transaction, his holdings increased to 435,500 shares — an increase of about 9.6%. This was the largest open-market purchase by a Pfizer insider in the past 12 months. Over the past year, Pfizer insiders have accumulated 114,900 shares, spending approximately $3 million; during the same period, only 5,280 shares — about $135,000 — were sold. Buying has far overwhelmed selling.

Still, insider ownership remains very low, accounting for only 0.03% of the company's total shares, worth about $44 million.

For a giant with over $60 billion in annual revenue, this figure is almost negligible. But as Simply Wall St's analysis noted, these holdings are "enough to indicate alignment of interests between insiders and other shareholders."

Bourla hasn't always been so bullish on his own stock.

In February 2025, he told CNBC: "Our stock is very cheap, with significant upside potential." But he didn't buy at the time. In March of the same year, as the stock rose, he sold over $5.4 million worth of shares — the company explained it was part of "personal financial planning" executed through a pre-arranged plan.

From selling to buying, from "talk" to "walk," Bourla's stance has shifted considerably.

On August 14, 2026, two days after the CEO's open-market purchase, Pfizer granted him 22 phantom stock units under a deferred compensation plan — each unit corresponding to one share of Pfizer common stock at $26.79. But phantom stock units are compensation; buying with one's own money is a different matter entirely.

This time, Bourla had truly put his own chips on the table.

Chapter 2: Why Now?

Bourla's timing was no coincidence.

Pfizer's Q2 2026 earnings tell a "mixed bag" story.

The good news: strong non-COVID performance. Eliquis sales reached $2.43 billion, up 19% year-over-year; Padcev grew 23%; Lorbrena grew 37%; the Vyndaqel family grew 8%.

The bad news: COVID products continue to drag down results. Paxlovid sales plunged 95% operationally; Comirnaty fell 34%. The company lowered its full-year COVID revenue expectation from approximately $5 billion to about $4 billion.

An even bigger shadow looms: the patent cliff. Between 2027 and 2028, Pfizer's core products will begin losing patent protection — oncology drug Ibrance (2027), cardiovascular drugs Eliquis and Vyndaqel (2028). The company expects the patent cliff to cause approximately $1.5 billion in sales erosion in 2026.

In other words, over the next two to three years, Pfizer must find new growth engines to fill this massive revenue gap.

Bourla said in the earnings statement that Pfizer delivered another strong quarter, meeting financial commitments and advancing its strategy. He noted that launched and acquired products performed well, the obesity program is advancing with meaningful momentum, and the oncology portfolio remains Pfizer's strength.

But the obesity story, at least, has been far more曲折.

Pfizer was an early mover in the oral GLP-1 race. From Lotiglipron to danuglipron (twice-daily) to clearing out all assets, Pfizer suffered repeated setbacks. In September 2025, Pfizer acquired Metsera for a total of around $10 billion, snatching from Novo Nordisk's grasp a biotech with a next-generation obesity pipeline — hoping to turn the tide.

Unexpectedly, less than a year later, the core oral asset from that acquisition was cut.

Chapter 3: A $10 Billion Bet, Half Gone

On August 4, Pfizer announced its latest pipeline adjustments in the Q2 earnings report: four programs cut at once. The most attention-grabbing was MET-224o's removal.

MET-224o was an oral, fully biased, ultra-long-acting GLP-1 receptor agonist — the core oral asset Pfizer acquired from Metsera. Pfizer and Novo Nordisk had engaged in a fierce bidding war for Metsera. Yet this drug, considered a "key layout for catching up," was abandoned in the first pipeline update after the acquisition closed.

Also cut was PF-07976016, a GIPR antagonist that had reached Phase IIa.

In December 2025, Pfizer licensed the oral small-molecule GLP-1 drug YP05002 from Fosun Pharma subsidiary Chongqing Yaoyou for a $150 million upfront payment. The plan was to combine PF-07976016 with YP05002 to challenge Eli Lilly's tirzepatide. But Phase IIa data proved disappointing; a Pfizer spokesperson confirmed the company decided to terminate development after evaluating the Phase IIa data on PF-07976016 combined with liraglutide.

With MET-224o terminated, Pfizer's oral GLP-1 assets from Metsera have been almost entirely stripped — another oral asset, MET-097o, had already disappeared in the first pipeline update after the acquisition closed.

Currently, Pfizer's oral GLP-1 pipeline consists only of PF-08642534 (YP05002), licensed from Chongqing Yaoyou.

But Pfizer hasn't lost everything. The injectable berobenatide (formerly MET-097i) acquired from Metsera has entered Phase III and become the core asset of Pfizer's obesity pipeline.

On the Q2 earnings call, Pfizer Chief Scientific Officer Chris Boshoff shared an analysis suggesting berobenatide's weight-loss efficacy could rival tirzepatide and potentially surpass semaglutide. Combined with data from the Phase IIb Vesper-1 trial's extension arm, Pfizer is increasingly confident in this once-monthly injectable candidate.

From repeated failures in self-developed oral GLP-1s to rapid cut-loss after a $10 billion acquisition, Pfizer's obesity strategy is undergoing a painful iteration.

This could be seen as a fast-fail strategy. But to investors, billions in upfront payments for assets that get cut within a year — even if "rational decision-making" — comes at a steep price.

Chapter 4: The Bet and the Uncertainty

Bourla's $1 million purchase pales in comparison to these numbers. But at the very least, it sends a clear signal: the captain believes the stock is undervalued.

Wall Street is not without consensus. The average target price among 28 analysts is $28.64; Morgan Stanley's Terence Flynn has a Hold rating and a $28 target; Bank of America's Jason Gerberry also raised his target to $27.

The difference between "Hold" and "Buy" reflects caution about Pfizer's transformation prospects.

Key focus areas ahead:

First, berobenatide's Phase III data. This is Pfizer's last trump card in obesity. If data are positive, Pfizer could launch the product in 2028–2029; if data disappoint, the Metsera acquisition's value would be significantly diminished.

Second, progress on oral GLP-1 PF-08642534 (YP05002). This is Pfizer's last remaining hope in the oral GLP-1 race. The company says it remains committed to exploring oral peptide and small-molecule approaches for GLP-1 receptor agonism.

Third, oncology pipeline performance. The core ADC assets acquired with the $43 billion Seagen acquisition in late 2023 failed to improve patient survival in a lung cancer trial in June. BMO Capital Markets analysts noted that ongoing questions about the Seagen deal's value suggest Pfizer "still needs to further clarify the scope and timing of its oncology business opportunities."

Meanwhile, Pfizer is undergoing management changes.

CFO Dave Denton left on August 15 to join Nike, with seasoned finance executive Cecile Guegan stepping in as interim CFO. Against the backdrop of a looming patent cliff, continued COVID revenue erosion, and uncertainty around key late-stage pipeline data, the company is advancing an additional cost-cutting plan that could save $2.5 billion between 2027 and 2029.

Bourla said on the earnings call that the company expects to return to strong growth after key patents expire in 2028. From 2028 to 2033, management projects revenue growth in the high single digits.

But these are still "projections." Before berobenatide's Phase III data read out, before oral GLP-1 clinical data emerge, before Seagen integration results become clear, Pfizer's stock may continue to hover around $26.

Bourla's $1 million is a bet on a future he believes will arrive. But when that future will arrive — and in what form — even the CEO himself cannot say with certainty.

And that, precisely, is what makes this bet so intriguing.

References:

• Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

• Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout

• The Mega Pharma Giant Can't Catch a Break; Tongxieyi

• Pfizer Loses Its Edge; Tongxieyi